Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study

BMJ

Volumn 336, Issue 7637, 2008, Pages 199-201

  Frank, B ^a   Serpell, M G ^b   Hughes, J ^c   Matthews, J N S ^d   Kapur, D ^e  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROCODEINE; NABILONE;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MOOD CHANGE; NEUROPATHIC PAIN; NIGHTMARE; OUTCOME ASSESSMENT; OUTPATIENT; OUTPATIENT DEPARTMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC DISEASE; CODEINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; PAIN; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 38949107918     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39429.619653.80     Document Type: Article

References (14)

1. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13-6.
2. Edwards JE, McQuay HJ, Moore RA. Single dose dihydrocodeine for acute postoperative pain. Cochrane Database Syst Rev 2000;(4):CD002760.
3. Luporini G, Barni S, Marchi E, Daffonchio L. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J 1998;12:97-101.
4. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
5. Notcutt WG. Clinical experience with nabilone for chronic pain. Pharmaceut Sci 1997;3:551-5.
6. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
7. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 1999;53:46-50.
8. Ware JE. SF-36 health survey: manual and interpretation guide. Lincoln, RI: Quality Metric, 2000.
9. Armitage P, Matthews JNS, Berry G. Statistical methods in medical research. 4th ed. Oxford, Malden, MA: Blackwell Science, 2002.
10. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999;353:560.
11. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88.
12. Frank B, Kapur D. Further experience with nabilone. Abstracts: Annual Scientific Meeting of the Pain Society 2001. London: British Pain Society, 2001:95.
13. Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-43.
14. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306.